摘要
目的:探讨冠心宁注射液联合依折麦布治疗冠心病心力衰竭(Coronary heart disease-heart failure,CHD-HF)患者的临床疗效及其应用价值。方法:选取2022年1月至2023年6月于本院诊治的94例CHD-HF患者资料进行回顾性分析,其中对照组(n=47)口服依折麦布(10 mg·次-1,1次·d-1)治疗,观察组(n=47)在此基础上静脉输注冠心宁注射液(20 mL·次-1,1次·d-1),共治疗1 m。比较两组临床疗效及治疗前、治疗1 m后测定心功能,包括左室射血分数(Left ventricular ejection fraction,LVEF)、左心室舒张末期内径(Left ventricular end diastolic dimension,LVEDD)、左心室收缩末期内径(Left ventricular end-systolic dimension,LVESD)、每分钟排血量(Cardiac output,CO);并采用ELISA法测定N-末端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)、可溶性生长刺激表达基因2(Soluble growth Stimulation expressed gene2,sST2)、胰岛素样生长因子-1(Insulin-like growth factor 1,IGF-1)、超氧化物歧化酶(Superoxide dismutase,SOD)、脂质过氧化物(Lipid peroxidation,LPO)水平;采用硫代巴比妥酸法测定丙二醛(Malondialdehyde,MDA)水平;比较两组不良反应与主要不良心血管事件(Major adverse cardiovascular events,MACE)发生率。结果:观察组总有效率高于对照组(P<0.05);观察组治疗后LVEF、CO高于对照组,LVEDD、LVESD低于对照组(P<0.05);观察组治疗后血清NT-proBNP、sST2、MDA、LPO水平低于对照组,IGF-1、SOD水平高于对照组(P<0.05);观察组治疗后6 m内MACE发生率低于对照组(P<0.05);两组不良反应比较无明显差异(P>0.05)。结论:冠心宁注射液联合依折麦布治疗CHD-HF患者疗效显著,可改善心功能,缓解氧化应激,降低MACE发生率。
Objective:To explore the clinical efficacy and application value of Guanxinning injection combined with ezetimibe in the treatment of coronary heart disease-heart failure(CHD-HF)patients.Methods:Retrospective analysis was conducted on the data of 94 CHD-HF patients treated in our hospital from January 2022 to June 2023.The control group(n=47)was treated with oral administration of ezetimibe(10 mg,once·day-1),while the observation group(n=47)was treated with intravenous infusion of Guanxinning injection(20 mL,once·day-1)on top of the control group.The treatment lasted for 1 month.The clinical efficacy of the two groups was compared,and cardiac function was measured before and after 1 month of treatment,including left ventricular ejection fraction(LVEF),left ventricular end diastolic dimension(LVEDD),left ventricular end systolic dimension(LVESD),and cardiac output(CO).The levels of N-terminal pro-brain natriuretic peptide(NT-proBNP),soluble growth stimulation expressed gene 2(sST2),insulin-like growth factor 1(IGF-1),superoxide dismutase(SOD),and lipid peroxidation(LPO)were measured using ELISA.The level of malondialdehyde(MDA)was determined using the thiobarbituric acid method.The incidence of adverse reactions and major adverse cardiovascular events(MACE)was compared between the two groups.Results:The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the LVEF and CO in the observation group were higher than those in the control group,while the LVEDD and LVESD were lower than those in the control group(P<0.05);The levels of NT-proBNP,sST2,MDA,and LPO in the observation group were lower than those in the control group after treatment,while the levels of IGF-1 and SOD were higher than those in the control group(P<0.05).The incidence of MACE in the observation group was lower than that in the control group within 6 months after treatment(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:The combination of Guanxinning Injection and Ezetimibe in the treatment of CHD-HF patients has significant therapeutic effects,which can improve cardiac function,alleviate oxidative stress,and reduce the incidence of MACE.
作者
王龙飞
徐亚威
赵荫涛
Wang Long-fei;Xu Ya-wei;Zhao Yin-tao(Department of Cardiovascular Medicine,Xinzheng Huaxin People's Hospital,Zhengzhou 451100,China;Department of Cardiovascular Medicine,Zhengdong Hospital,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
关键词
冠心病
心力衰竭
冠心宁
依折麦布
疗效
Coronary heart disease
Heart failure
Guanxinning
Ezetimibe
Therapeutic effect
